Pharvaris (PHVS) Cash from Investing Activities (2020 - 2026)
Pharvaris (PHVS) posted Cash from Investing Activities of -$60992.3 for Q1 2026, down 3306.82% on a QoQ basis from -$1790.3 in Q4 2025, and up 63.99% year-over-year from -$37193.7 in Q1 2025.
Pharvaris (PHVS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Pharvaris' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$60992.3 for Q1 2026.
- Quarterly Cash from Investing Activities rose 63.99% year-over-year to -$60992.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$65829.1 (up 90.87% YoY) and the FY2025 annual result came in at -$185988.4, up 68.06% from the prior year.
- Cash from Investing Activities was -$60992.3 for Q1 2026 at Pharvaris, down from -$1790.3 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $58.9 billion in Q3 2023 and bottomed at -$58.9 billion in Q2 2023.
- A 5-year average of -$1.1 million and a median of -$30535.2 in 2023 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 114742419.94% in 2023, while the deepest fall reached 236328759.87% in 2023.
- Pharvaris' Cash from Investing Activities stood at -$24117.6 in 2022, then retreated by 26.61% to -$30535.2 in 2023, then tumbled by 463.14% to -$171955.2 in 2024, then surged by 98.96% to -$1790.3 in 2025, then sank by 3306.82% to -$60992.3 in 2026.
- Business Quant data shows PHVS's Cash from Investing Activities at -$60992.3 in Q1 2026, -$1790.3 in Q4 2025, and -$21877.7 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | - |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Pharvaris | 2.23 Bn | 1.94 Bn | - | -60,992.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60,992.34 |
| Mar 31, 2026 | -60,992.34 |
| Dec 31, 2025 | -1,790.30 |
| Dec 31, 2025 | -1,790.30 |
| Sep 30, 2025 | -21,877.70 |
| Sep 30, 2025 | -21,877.70 |
| Jun 30, 2025 | 18,831.28 |
| Jun 30, 2025 | 18,831.28 |
| Mar 31, 2025 | -169,356.55 |
| Mar 31, 2025 | -169,356.55 |
| Dec 31, 2024 | -171,955.17 |
| Dec 31, 2024 | -171,955.17 |
| Sep 30, 2024 | -336,412.09 |
| Sep 30, 2024 | -336,412.09 |
| Jun 30, 2024 | -43,221.96 |
| Jun 30, 2024 | -43,221.96 |
| Mar 31, 2024 | -33,360.00 |
| Mar 31, 2024 | -33,360.00 |
| Dec 31, 2023 | -30,535.17 |
| Dec 31, 2023 | -30,535.17 |